lundi 11 mai 2020

Onco Actu du 11 mai 2020


4.12 BIOPSIES LIQUIDES



Blood test for cancer detection company Grail rakes in $390M in latest round [EndPoints]











Prospective Study Adds Evidence for CellMax Life Liquid Biopsy Utility in CRC Screening [Genome Web]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



More Selective Elimination of Leukemia Stem Cells and Blood Stem Cells [University of Zurich]











5.2 PHARMA



Enhertu granted Breakthrough Therapy Designation in the US for HER2-positive metastatic gastric cancer [AstraZeneca]











5.2.6 PHARMA - BIOTECH



Nanobiotix announces first phase I trial with NBTXR3 in pancreatic cancer is safe to proceed per US FDA [Nanobiotix]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Novartis wins approval for niche lung cancer drug [Biopharma Dive]











Approval of targeted therapies first line for prostate cancer ‘will ease COVID-19 pressures’ [Institute of Cancer Research]











Encorafenib, Cetuximab Combination Approved for Metastatic Colorectal Cancer [NCI]











5.3.4.1 TRAITEMENTS - AMM (FDA, EMA,...) - SELPERCATINIB



A groundbreaking cancer drug nabs fast OK, giving Eli Lilly boasting rights as a rival speeds close behind [EndPoints]











Lilly's Loxo buyout bears fruit as FDA clears cancer drug Retevmo [Biopharma Dive]











FDA approves Eli Lilly drug for thyroid, lung cancers driven by a genetic mutation [Reuters]











Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers [Lilly]











FDA Approves First Therapy for Patients with Lung and Thyroid Cancers with a Certain Genetic Mutation or Fusion [FDA]










Eli Lilly Gets Edge in the “RET” Race With FDA Nod for Cancer Drug [Xconomy]











5.3.4.2 TRAITEMENTS - AMM (FDA, EMA,...) - OLAPARIB



LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer [Merck]











5.4 TRAITEMENTS - ECONOMIE



NICE draft guidance recommends new treatment option for people with early breast cancer [Nice]











Roche's Kadcyla wins NICE backing in early breast cancer use [Fierce Pharma]










5.5.1.1 ASCO (GÉNÉRAL) - INDUSTRIELS



Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program [Merck]











New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment to accelerating progress in cancer care [Roche]











bluebird bio to Present Updated Results From Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma During ASCO20 Virtual Scientific Program [bluebird bio]











6.15 LUTTE CONTRE LES CANCERS - COVID-19



Androgen-deprivation treatments for prostate cancer could protect men from COVID-19 [EurekAlert!]










More than 1,000 clinical trials were stopped by the pandemic — including dozens in PhIII [EndPoints]











Survey: Half of Cancer Researchers Report Their Work is on Hold [ACS]